soluble il-18 receptor complex a new star in the firmament of rheumatoid arthritis diagnosis可溶性地震-受体复杂的一颗新星在类风湿关节炎诊断的苍穹.pdf

van de Loo Arthritis Research Therapy 2011, 13:111 /content/13/2/111 E D I TO R I A L Soluble IL-18 receptor complex: a new star in the i rmament of rheumatoid arthritis diagnosis? Fons AJ van de Loo* See related research by Takei et al., /content/13/2/R52 specifi c for RA and of great prognostic value for the Abstract outcome of disease [2]. It is important to monitor disease It has long been recognized that laboratory tests activity during therapy in order to adjust, change or even are useful in the diagnosis of disease and to monitor stop therapy when necessary. h is is the reason that the treatment outcome. Their performance has become search for new biomarkers that can be used to monitor or even more demanding with the development of even predict therapeutic eff ectiveness is still ongoing. personalized medicine. In patients with rheumatoid arthritis (RA) the standard biochemical tests measure Biomarkers identifi ed by -omics serological markers of disease, such as C-reactive h e major problem is that RA is a heterogeneous disease, protein, and RA-associated auto-antibodies, such with disease course and extent of connective tissue as rheumatoid factor and anti-citrullinated protein destruction varying considerably among patients. Histo- antibodies. The information obtained from these logical evaluation of the infl amed synovium confi rms the markers does not, however, provide a complete picture heterogeneity in RA, and cDNA microarray analysis of of the disease and treatment efficacy. New biom